

9

MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 <u>technicalservices@medisca.net</u>

7/1/2020; Page 1

Suggested	Pyridoxine Hydrochloride 100 mg/mL Injection (Solution, 50 mL)	FIN	F 001 504v3	
Formula				

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Pyridoxine Hydrochloride, USP	5.000	g				
Chlorobutanol, NF	0.25	g				
Sterile Water for Injection, USP	40.0	mL				
Sterile Water for Injection, USP	q.s. to 50.0	mL				
Sodium Hydroxide 10% Solution	As required					
Hydrochloric Acid 10% Solution	As required		(B)			

SPECIAL PREPARATORY CONSIDERATIONS


Ingredient-Specific Information

Light Sensitive (protect from light whenever possible):

Pyridoxine Hydrochloride



7/1/2020; Page 2





7/1/2020; Page 3

Suggested Formula	Pyridoxine Hydrochloride 100 mg/mL Injection (Solution, 50 mL)	FIN	F 001 504v3	
----------------------	--	-----	-------------	--

SUGGESTED PREPARATION (for 50 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) :	Processing Error	Qty. to measure
Pyridoxine Hydrochloride, USP §	5.000	g			
Chlorobutanol, NF §	0.25	g			
Sterile Water for Injection, USP §	40.0	mL			
Sterile Water for Injection, USP §	q.s. to 50.0	mL			
Sodium Hydroxide 10% Solution §	As required		14		
Hydrochloric Acid 10% Solution §	As required	5	4		

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

	Preparatory Instruction							
	IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique							
1.	Equipment sterilization:							
	Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.							
2.	Powder preparation:							
	A. Triturate the following ingredients together, to form a fine homogeneous powder blend:							
	-Pyridoxine Hydrochloride -Chlorobutanol							
3.	Powder to medium integration:							
	A. Incrementally add the fine homogeneous powder blend (Step 2A) into the Sterile Water for Injection (40.0 mL plus processing error adjustments).							
	Specifications: Continuously mix until all solid particles have completely dissolved.							
	End result: Homogeneous liquid-like solution.							



7/1/2020; Page 4

~	Suggested FormulaPyridoxine Hydrochloride 100 mg/mL Injection (Solution, 50 mL)FINF 001 504							
4.	pH testing:							
	A. Draw an appropriate amount of the mixture (Step 3A).							
	B. Test the pH of the sample. It should lie between 2.0 and 3.8.							
	C. If the pH < 2.0, carefully add in a dropwise manner the Sodium Hydroxide 10% Solution to the mixture:							
	 Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% Solution to the mixture. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% Solution. Re-test the pH. Continue to add the Sodium Hydroxide 10% Solution until the pH of 2.0 to 3.8 is obtained. IMPORTANT: Do not allow the pH to rise above 3.8. 							
	D. If the pH > 3.8, carefully add in a dropwise manner the Hydrochloric Acid 10% Solution to the mixture:							
	 Draw and transfer 1 or 2 drops of the Hydrochloric Acid 10% Solution to the mixture. Stir for at least 5 minutes to evenly disperse the Hydrochloric Acid 10% Solution. Re-test the pH. Continue to add the Hydrochloric Acid 10% Solution until the pH of 2.0 to 3.8 is obtained. 							
	IMPORTANT: Do not allow the pH to fall below 2.0.							
5.	Filling to volume:							
	A. Add additional Sterile Water for Injection to the above mixture to fill to the required batch size (50.0 mL <i>plus</i> processing error adjustments).							
	Specifications: Continuously mix.							
	End result: Homogeneous liquid-like solution.							
6.	Filtering and transferring:							
	Aseptically filter the solution through a 0.22 - μ m sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.							
7.	Filter integrity test:							
	Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, t solution must be discarded and remade.	he						



7/1/2020; Page 5

Suggeste Formu		0	Pyridoxine Hydrochloride 100 mg/mL Injection (Solution, 50 mL)	FIN	F 001 504v3				
	8. <u>Terminal Sterilization:</u>								
		In relation to the chemical composition of the formulation, final packaging, etc., select and validate an end-sta sterilization method and follow the manufacturer's specification.							
	9.	Sterility and Endotoxin testing:							
	Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.								
			(Q-)						

SUGGESTED PRESENTATION

UGGESTED PRESEN			NIATION			
В	Estimated Beyond-Use Date			Packag		Sterile, light-resistant injection vials.
		1	Use as directed. Do not exceed prescril dose.	bed	7	Discard container after use.
		2	Keep out of reach of children.	\geq	8	Hypertonic solution, inject slowly.
	Auxiliary	3	Keep at controlled room temperature, (20 -25° C), refrigerated (2°C -8° C) or from (-25°C to -10°C).		9	Protect from light.
	Labels	4	Equilibrate to room temperature before u	ise.	10	Do not use if discolored.
		5	Discard in the presence of particulate mat	tter.	11	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.
		6	Do not take with alcohol, sleep as tranquilizers or other CNS depressants.	ids,	12	May impair mental and/or physical ability. Use care when operating a car or machinery.
Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as deer				nsing container as deemed necessary.		
	Patient Instructions Contact your pharmacist in the event of adverse reactions.				IS.	



7/1/2020; Page 6

	Suggested Formula	FIN	F 001 504v3					
EFE		6						
1.	Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 1998: 251.							
2.	Chlorobutanol. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4th Edition</i> . American Pharmaceutical Association; 2003: 141.							
3.	• Pyridoxine Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 34th Edition</i> . London, England: The Pharmaceutical Press; 2005: 1456.							
4.	1 yiiu	Pyridoxine Hydrochloride (Monograph). In: O'Neil MJ. <i>The Merck Index 13th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 1429.						
5.	Chap	Chapter 18: Tonicity, Osmoticity, Osmolality and Osmolarity. In: AR Gennaro, Remington: <i>The science and practice of pharmacy</i> , 20 th pp. 246~262.						
6.	Pyridoxine Hydrochloride. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations</i> , 2 nd Edition. American Pharmaceutical Association; 2000: 330.							
7.	1 yiiu	Pyridoxine Hydrochloride (Monograph). US Pharmacopeial Convention, Inc. United States Pharmacopeia XXV / National Formulary 20. Rockville, MD: 2001: 1494.						
8.	0.51	USP <797> Pharmaceutical Compounding – Sterile Preparations. US Pharmacopeial Convention, Inc. United States Pharmacopeia XXVIII / National Formulary 23. Rockville, MD. 2004: 2461.						

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2019-2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW, MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER PARTY. AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER PARTY. AND IT IS THE RESPONSIBILITY OF T